Table 6.

The change of patient affordability for mPFS treatment course before and after the NHIC policy.

Name	Indication	Treatment course base on mPFS	Before				After
			OOP (patient without PAP, CNY)	Affordability	OOP (patient with PAP, CNY)	Affordability	OOP (CNY)	Affordability
Rituximab	Lymphoma	6.7 M	873,596	U:16.02,R:37.76	—	—	112,659	U:1.90, R:4.46
Trastuzumab	Breast cancer	1 Y	364,989	U:6.69, R:15.78	156,424	U:2.87,R:6.76	25,218	U:0.43, R:1.00
Bevacizumab	Colorectal cancer	6.1M	237,900	U:4.36, R:10.28	156,000	U:2.86,R:6.74	18,282	U:0.31, R:0.72
Sorafenib	Kidney cancer	5.7 M	285,001	U:5.23, R:12.32	150,000	U:2.75,R:6.48	27,770	U:0.47, R:1.10
Bortezomib	Mantle cell lymphoma	14.9 M	645,213	U:11.83,R:27.89	215,071	U:3.94,R:9.30	62,488	U:1.58, R:3.71
Erlotinib	Non-small cell lung cancer	7.5 M	103,500	U:1.90, R:4.47	55,200	U:1.01,R:2.39	8,775	U:0.15, R:0.35
Nimotuzumab	Nasopharynx cancer	7 M	204,204	U:3.74, R:8.83	—	—	20,420	U:0.52, R:1,21
Apatinib	Gastric adenocarcinoma	2.6 M	57,045	U:1.05, R:2.47	—	—	7,213	U:0.06, R:0.14
Fulvestrant	Breast cancer	4.6 M	34,798	U:0.64, R:1.50	16,312	U:0.30,R:0.71	2,199	U:0.06, R:0.13
Everolimus	Kidney cancer	4.9 M	72,765	U:1.33, R:3.15	—	—	8,702	U:0.22, R:0.52
Lenalidomide	Multiple myeloma	10M	631,338	U:11.58,R:27.29	—	—	49,589	U:1.25, R:2.94
Recombinant human endostatin	Non-small cell lung cancer	6 M	97,949	U:1.80, R:4.23	—	—	12,852	U:0.33, R:0.76

Before the NHIC policy intervention, the per capita annual disposable income was CNY 54,538 in urban area and CNY 21,333 in rural area; after the NHIC policy intervention, the per capita annual disposable income was CNY 59,308 in urban area and CNY 25,263 in rural area.

U, Urban; R, Rural.

M, Months; Y, Year.